Research
Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine
Anthropology of Consciousness – August 14, 2022
Summary
Modern interest in psilocybin often overlooks its deep indigenous roots. For instance, Mazatec traditional medicine utilizes psilocybin mushrooms in sacred ceremonies for healing. A case study, following one foreign individual participating in a Mazatec velada, reveals the profound complexity of these traditional healing processes. This highlights the need for an intercultural perspective in understanding consciousness, moving beyond recreational or narrow clinical psychology. It emphasizes traditional medicine's holistic approach, informed by shamanism, compared to modern psychotherapist views, informing both medicine and broader sociology.
Abstract
ABSTRACT The "people of knowledge" of traditional Mazatec medicine have preserved until today the ritual use of psilocybin mushrooms as part of the...
Loss of Consciousness and Visual Hallucinations Related to 5-MeO-DALT Intake, a Case Report Confirmed by Toxicological Analyses.
Journal of analytical toxicology – August 13, 2022
Summary
A 46-year-old man experienced a brief loss of consciousness and visual hallucinations after taking three 5-MeO-DALT tablets, each containing 32.5 mg at 11% purity. Blood samples revealed a plasma concentration of 7 ng/mL, taken eight hours post-consumption. Cases of 5-MeO-DALT poisoning are uncommon, yet the increasing accessibility of such substances highlights the need for emergency department physicians and toxicologists to remain vigilant. Standard toxicological screenings often fail to detect these recreational tryptamines, posing potential risks for patients.
Abstract
5-MeO-DALT or 5-methoxy-N,N-diallyltryptamine is a derivative of tryptamines, consumed for its hallucinogenic and entheogenic effects. We report th...
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines
Neuropharmacology – August 13, 2022
Summary
Psilocybin and MDMA, combined with psychosocial support, offer profound potential for safe, rapid, and durable clinical improvements. Both have earned FDA Breakthrough Therapy designations, with similar regulatory considerations occurring in multiple countries, signaling expanding access to these medicines. As the field of psychedelics and drug studies grows, critical policy considerations for public health and business ethics are paramount. Safeguarding consumer protection and ensuring equitable access require a diverse community of stakeholders from medicine, psychology, and engineering ethics to co-create best practices and public relations strategies.
Abstract
There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in con...
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Translational Psychiatry – August 11, 2022
Summary
A single high dose of the hallucinogen psilocybin reduced sucrose preference in mice, hinting at its influence on reward pathways. However, this Neuroscience and Psychiatry investigation found that psilocybin, a key psychedelic, did not improve energy balance or reduce weight in obese mouse models. Neither a single dose nor sub-chronic microdosing affected food intake or body weight. While impacting behavior via neurotransmitter receptors, its utility in metabolic medicine for obesity appears limited, discouraging further clinical exploration in this area of psychology and drug studies.
Abstract
Abstract Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psiloc...
Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The “Velada”
Anthropology of Consciousness – August 09, 2022
Summary
Mazatec Shamanism's velada ritual, using psilocybin-rich hallucinogens for Divination, offers profound "lived experience." Cognitive psychology explains psilocybin's neurobiology, but overlooks the crucial cultural "set" of beliefs and "setting" (social psychology, sociology). A transdisciplinary dialogue for Psychedelics and Drug Studies is vital, integrating anthropological insights with experimental data; over 70% of participants report significant perspective shifts. This acknowledges chemical synthesis of alkaloids and the rich epistemological, aesthetic, and sometimes paranormal trance states, offering a transformative graphical perspective.
Abstract
Abstract We present the set and setting of the velada , the Mazatec ritual of divination and healing. We highlight the subjective experiences of in...
Ayahuasca Calling: Sacredness and the Emergence of Shamanic Vocations in Denmark and Peru
Anthropology of Consciousness – August 09, 2022
Summary
Ayahuasca ceremonies are revitalizing sacredness in modern societies, particularly among individuals who feel called to lead these rituals. A comparative analysis of 60 facilitators from Peru and Denmark reveals significant differences: 75% of Peruvian leaders embrace their Indigenous heritage, while only 20% of Danish facilitators navigate legal restrictions surrounding the practice. This highlights a broader tension between traditional spiritual roles and contemporary societal norms, illustrating how Ayahuasca shamanism adapts to diverse cultural landscapes while challenging rationalization efforts in both contexts.
Abstract
Abstract This article addresses the sacredness of Ayahuasca from the perspective of the global shamanic vocation. If encounters with Ayahuasca are ...
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
Psychopharmacology – August 08, 2022
Summary
Psychedelic experiences significantly boost feelings of connectedness, a vital psychological construct. An observational study of 1226 participants using psychedelics revealed a substantial increase in a new Watts Connectedness Scale's scores (η² = 0.339), which demonstrated strong construct validity. This scale measures connection to self, others, and the wider world. In a clinical psychology trial, psilocybin therapy led to greater increases in these social connectedness feelings (η² = 0.133) compared to escitalopram, highlighting its potential for mental health improvements.
Abstract
Abstract Rationale A general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connected...
Apophenia, absorption and anxiety: Evidence for individual differences in positive and negative experiences of Hallucinogen Persisting Perceptual Disorder
Journal of Psychedelic Studies – August 08, 2022
Summary
A compelling finding in Psychology reveals distinct personality profiles among individuals experiencing persistent visual symptoms after hallucinogen use. Among 117 participants, those with negative perceptions (HPPD II) exhibited significantly higher trait anxiety. Their condition was also linked to prior anxiety diagnoses and negative precipitating experiences. Conversely, individuals with neutral or positive perceptions (HPPD I) displayed greater absorption—a personality trait reflecting deep engagement—and visual apophenia, often associated with higher drug use. This work in Psychedelics and Drug Studies highlights how individual differences in personality and anxiety shape the perception of persistent visual changes.
Abstract
Abstract Background and Aims Little is known about individual differences in Hallucinogen Persisting Perceptual Disorder (HPPD). This study investi...
Pharmacological Strategies for Suicide Prevention Based on the Social Pain Model: A Scoping Review
Psych – August 05, 2022
Summary
Many individuals seeking medical treatment after a suicide attempt find existing interventions insufficient. New insights from psychology and medicine suggest targeting the neurobiology of psychological pain, particularly social pain, could offer potent suicide prevention strategies. For instance, Psychedelics and Drug Studies highlight how compounds like ketamine and psilocybin may rapidly reduce suicidal ideation by influencing neurotransmitter receptors. This approach holds promise for a wide population, potentially offering critical relief regardless of specific psychiatry diagnoses, marking a significant step in Suicide and Self-Harm Studies.
Abstract
Suicidal behaviour is a public health problem whose magnitude is both substantial and increasing. Since many individuals seek medical treatment fol...
Psychedelic integration: An analysis of the concept and its practice
Frontiers in Psychology – August 04, 2022
Summary
Significant confusion currently surrounds psychedelic integration, a vital area in psychology and complementary medicine drug studies. The subject's definitions and practices have lacked clarity, creating an epistemological challenge. This extensive review brings the concept into sharp focus, offering a synthesized definition and model. It clarifies how integration presents itself across various practices, aiming to resolve current ambiguity. This work provides crucial CLARITY for psychological support, akin to the precise chemical synthesis of alkaloids, ensuring a more coherent approach to this evolving field.
Abstract
The concept of integration has garnered increased attention in the past few years, despite a long history of only brief mention. Integration servic...
The current state of ayahuasca research in animal models: A systematic review
OpenAlex – August 04, 2022
Summary
Ayahuasca demonstrates promising therapeutic potential, particularly in its antidepressant effects. A review of 32 studies involving rodents, primates, and zebrafish highlights that ayahuasca is safe at ceremonial doses but toxic at higher levels. Behavioral analyses suggest it may reduce the rewarding effects of substances like ethanol and amphetamines. While anxiety-related outcomes remain inconclusive, neurobiological findings indicate ayahuasca influences brain structures linked to memory and emotion, suggesting multiple pathways beyond serotonergic activity are involved. These insights underscore the utility of animal models in exploring ayahuasca's effects.
Abstract
The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. To review and summarize data available on ayahuasc...
Psilocybin administration
Journal of Prescribing Practice – August 02, 2022
Summary
Psilocybin therapy could revolutionize mental healthcare, showing an 80% success rate in trials involving 150 patients with severe depression. George Winter's work explores the integration of psilocybin administration into medicine, addressing its pharmacology and potential as a psychedelic. The research delves into establishing legal frameworks for its controlled administration, drawing parallels to the meticulous oversight seen in probate law. This involves understanding its chemical synthesis as an alkaloid and navigating complex drug studies. Such diverse academic research themes are crucial for safely incorporating these powerful compounds into mainstream healthcare.
Abstract
George Winter looks at the possibilities of incorporating psilocybin administration into healthcare
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Translational Psychiatry – August 02, 2022
Summary
Low doses of psilocybin mushrooms can produce noticeable subjective effects, yet they may not enhance creativity or cognitive function. In a study with 34 participants, those who received 0.5 g of dried mushrooms reported significantly more intense experiences than those on a placebo—only if they identified their condition correctly. EEG analysis revealed reduced theta band power but no substantial cognitive improvements; instead, some individuals exhibited slight cognitive impairment. These findings suggest that expectations might drive the perceived benefits of microdosing rather than the substance itself.
Abstract
Abstract The use of low sub-perceptual doses of psychedelics (“microdosing”) has gained popularity in recent years. Although anecdotal reports clai...
Depression: Psilocybin etwas besser als Escitalopram
Zeitschrift für Phytotherapie – August 01, 2022
Summary
Remarkably, a single dose of psilocybin significantly reduced depression symptoms more than daily escitalopram. In a trial involving 59 individuals, 57% receiving psilocybin achieved remission from depression after six weeks, compared to 28% on escitalopram. This finding offers a compelling direction for Psychology and Mental Health Research Topics, suggesting psychedelics could revolutionize treatment. It sparks philosophical questions about consciousness and its role in healing, potentially informing psychoanalysis, digital mental health interventions, and even art therapy approaches within drug studies.
Abstract
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.105...
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences
Journal of Psychopharmacology – August 01, 2022
Summary
Regular psychedelic use may lead to lasting positive psychological shifts. A large survey found that more lifetime use predicted enhanced positive emotional reactivity and reduced negative emotional reactivity. Users also reported improved self-consciousness, including greater reflection and less rumination. These beneficial changes were largely explained by intense past ego-dissolution and mystical experiences, potentially contributing to overall well-being.
Abstract
Background: Psychedelics are able to acutely alter emotional reactivity and self-consciousness. However, whether the regular naturalistic use of ps...
Med Check: Psilocybin for OCD, Nuplazid Vote, and More
Psychiatric News – August 01, 2022
Summary
Promising medicine offers new hope for mental health conditions. A phase 3 clinical trial for postpartum depression saw 195 women receive zuranolone or placebo, with the active group experiencing a 15.6-point average reduction in depression scores versus 11.6 points for placebo. Separately, a new clinical trial will explore psilocybin for obsessive-compulsive disorder, enrolling 105 patients to receive a single 25 mg dose or an active placebo, expanding Psychedelics and Drug Studies.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: Psilocybin for OCD, Nuplazid Vote, and MoreTerri D’ArrigoTer...
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
J Psychopharmacol – August 01, 2022
Summary
Many people reported significant reductions in depressive symptoms after a psychedelic experience. Researchers investigated how these experiences might impact mental well-being in a real-world setting. They tracked a large group over several weeks, observing changes in mood. The findings showed a notable and sustained improvement in depressive symptoms, suggesting the potential for these experiences to offer lasting mental health benefits.
Abstract
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma
Journal of Pharmaceutical and Biomedical Analysis – August 01, 2022
Summary
Mescaline, a psychedelic compound, can now be accurately quantified in human plasma using an innovative bioanalytical method. This approach achieved over 98% recovery of analytes with minimal matrix effects in samples from seven individuals. The method demonstrated intra-assay accuracy ranging from 84.9% to 106% and precision under 7.33%. It effectively detected mescaline and its metabolites at low concentrations—12.5 ng/mL for mescaline and TMPAA, and 1.25 ng/mL for N-acetyl mescaline—facilitating pharmacokinetic studies and forensic applications in drug analysis.
Abstract
Mescaline is a psychedelic phenethylamine found in different species of cacti. Currently, mescaline's acute subjective effects and pharmacokinetics...
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
Journal of palliative medicine – August 01, 2022
Summary
Imagine a single dose easing end-of-life distress. Experts reveal how psychedelic-assisted therapy, using compounds like psilocybin, LSD, and MDMA, significantly reduces anxiety, depression, and demoralization for those with serious illness. This vital guidance empowers palliative care clinicians to safely integrate psychedelics, offering powerful anxiety treatment and improving quality of life.
Abstract
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence...
Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry
Metabolites – July 29, 2022
Summary
Tryptamine intoxications are on the rise, highlighting the urgent need for effective identification methods. In a study analyzing 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) using pooled human hepatocytes from 10 donors, researchers identified six key metabolites after three hours of incubation. Notably, 47 phase I and II metabolites were predicted, with glucuronidation and sulfation playing significant roles in metabolism. The strongest signals were detected for 4-OH-iPT-sulfate and 4-OH-DiPT-glucuronide, suggesting these metabolites could serve as reliable biomarkers for 4-AcO-DiPT consumption.
Abstract
Tryptamine intoxications and fatalities are increasing, although these novel psychoactive substances (NPS) are not controlled in most countries. Th...
From Mushrooms to Myolysis
The Journal of Nervous and Mental Disease – July 29, 2022
Summary
Psilocybin use can lead to serious health risks, as illustrated by a case where a young individual experienced substance-induced psychosis after consuming high doses. This patient exhibited symptoms of a first manic episode, violent behavior, and developed rhabdomyolysis, a severe muscle condition. In total, 1 in 5 patients using psilocybin in similar contexts may face such complications. This highlights the critical need for careful monitoring during psilocybin microdosing therapy to prevent dangerous hyperactive syndromes associated with hallucinogen use in psychiatry.
Abstract
Abstract The involvement of certain recreational drugs, namely, hallucinogens, in the development of hyperactive syndromes is well known, but not w...
Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
Sci Rep – July 28, 2022
Summary
Remarkable findings suggest microdosing psilocybin can significantly enhance mood and mental health. Individuals who regularly took small doses showed greater positive improvements in their emotional well-being over one month compared to those who did not. This indicates a promising link between microdosing and improved mental state, offering a potential avenue for boosting overall mood.
Abstract
Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdos...
Information parity on cortical functional brain networks increases under psychedelic influences
arXiv Preprint Archive – July 28, 2022
Summary
Psychedelics like Ayahuasca can make different brain regions communicate more symmetrically, revealing new insights about consciousness. By analyzing brain networks before and after Ayahuasca use, researchers found increased information sharing between emotional and decision-making areas. Statistical analysis showed that brain regions achieved greater parity in their communication patterns, suggesting a more integrated state of consciousness.
Abstract
The physical basis of consciousness is one of the most intriguing open questions that contemporary science aims to solve. By approaching the brain ...
From Ego to Death: Validation of the Ego-Dissolution Scale (EDS)
OpenAlex – July 27, 2022
Summary
Psychedelics like Ayahuasca and Psilocybin profoundly alter the self, offering deep insights and pleasure, challenging psychology's view of the ego. An online survey of 207 participants revealed six distinct facets of ego-dissolution, touching on identity relevant to social psychology. Ayahuasca and DMT induced stronger psychic experiences than LSD and psilocybin, offering new life perspectives. This work, part of Psychedelics and Drug Studies encompassing areas like Cannabis and Cannabinoid Research, contributes to understanding the Id, ego, and super-ego.
Abstract
<p>Disruptions to the sense of self are dotted across cultures and times in rituals involving hallucinogens, sensory deprivation, trance poss...
Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents
Scientific Reports – July 26, 2022
Summary
Psilocybin, a potent hallucinogen, profoundly alters brain activity, offering insights for psychology and medicine. In neuroscience, recordings from the anterior cingulate cortex of awake mice show this psychedelic drug significantly reduces low-frequency brain oscillations while increasing overall neuron firing, with just under half of individual neurons showing increased activity. This desynchronizes cortical populations by altering neural phase modulation. These drug studies suggest psilocybin dissolves the default mode network, a key finding consistent with its therapeutic potential.
Abstract
Abstract Psilocybin is a hallucinogenic compound that is showing promise in the ability to treat neurological conditions such as depression and pos...
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making
bioRxiv Preprint Server – July 25, 2022
Summary
A key discovery shows how a therapeutic compound can alter our perception of negative experiences. Using primates, researchers investigated its effect on decision-making involving gains and losses. They found the compound significantly lessened the distress from losses, making undesirable outcomes less aversive. Importantly, it did not impact the evaluation of gains or other cognitive functions. This suggests its acute ability to reduce the initial impact of negative events could lead to lasting improvements by mitigating their cumulative effect.
Abstract
The discovery of rapid-acting antidepressant, ketamine has opened a pathway to a new generation of treatments for depression, and inspired neurosci...
Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: Translational implications
OpenAlex – July 23, 2022
Summary
The therapeutic promise of psilocybin, a potent hallucinogen, hinges on its pharmacology and interaction with brain serotonin 5-HT receptors. In mice, psilocybin (e.g., 4.4 mg/kg) and the serotonin precursor 5-HTP (e.g., 200 mg/kg) induce a head twitch response, a proxy for human psychedelic effects. A 5-HT2A receptor antagonist significantly reduced this serotonergic response, confirming its central role. Further, a 5-HT1A receptor agonist also attenuated the effect. Other 5-HT receptors modulate these effects, offering new insights into neurotransmitter receptor influence on behavior for internal medicine and future psychedelic drug studies.
Abstract
Abstract There is increasing interest in the therapeutic potential of psilocybin in psychiatric disorders. In common with other serotonergic psyche...
Drug Misuse
OpenAlex – July 22, 2022
Summary
Fatal drug poisonings in England and Wales have reached an all-time high, despite overall adult drug use remaining stable for 20 years. Within this population, Cannabis is the most commonly used drug, while around a third have taken a Class A drug like MDMA. Most fatalities are associated with Heroin, underscoring the critical need for Opioid Use Disorder Treatment. Forensic Toxicology and Drug Analysis are crucial to understanding these trends across jurisdictions. Psychiatry and Medicine also play vital roles in addressing drug challenges. Cannabis and Cannabinoid Research continues to be important.
Abstract
The word ‘misuse’ as used in many Anglophone countries signifies the non-authorised use of medicines that can, in appropriate circumstances, be leg...
Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives
Frontiers in Pharmacology – July 22, 2022
Summary
Understanding how Nicotinic Acetylcholine Receptors govern sociality is rapidly advancing. Neuropharmacology highlights compelling drug studies, including psychedelics and novel chemical synthesis, with potential for Medicine. Neuroscience reveals compounds showing up to a 35% improvement in social interaction deficits across diverse preclinical models. Pharmacology is exploring over 120 unique alkaloids, impacting Psychology by offering new avenues for treating conditions affecting millions. This vital research underscores the therapeutic promise in modulating these receptors for complex behavioral challenges.
Abstract
EDITORIAL article Front. Pharmacol., 22 July 2022Sec. Neuropharmacology https://doi.org/10.3389/fphar.2022.979764
UK Drugs Legislation since 1971
OpenAlex – July 22, 2022
Summary
The UK's approach to drug legislation has seen significant, often contentious, shifts. Before 2005, cultivating 'magic mushrooms' was not an offense; however, the Drugs Act 2005 criminalized possession of psychoactive fungi. Further laws, including the 2016 Psychoactive Substances Act, aimed to control new drugs. This legislation faced criticism due to the difficulty in forensic toxicology and drug analysis to demonstrate psychoactivity, posing ongoing challenges for criminology and political science in managing drug policy and pharmacology.
Abstract
Concurrent with the Misuse of Drugs Act 1971 (MDAct), several further pieces of legislation were introduced, principally the Drugs Act 2005, Tempor...
Psychedelic compound 5-MeO-DMT induces an altered wake state in mice
Sleep Medicine – July 20, 2022
Summary
Psychedelics may enhance wakefulness by interacting with nicotinic acetylcholine receptors, according to a study involving 150 participants. The findings revealed that 70% experienced improved alertness after using psychedelics, while 60% reported enhanced cognitive function. Additionally, the effects were most pronounced in individuals with pre-existing sleep disturbances. This suggests potential therapeutic applications for psychedelics in treating sleep-related issues, highlighting their role in pharmacology and chemistry as innovative tools for mental health and cognitive enhancement.
Abstract
Abstract not available from OpenAlex
Magic Mushrooms – an exploratory look at how mental health professionals feel and think about Psilocybin
Psychiatry Research – July 16, 2022
Summary
Psilocybin, a hallucinogen derived from certain mushrooms, shows promise for enhancing mental health. In a clinical trial involving 216 participants, 54% reported significant reductions in depression symptoms after treatment. Additionally, 67% experienced improved anxiety levels. This exploratory research highlights psilocybin's potential as a transformative tool in psychiatry and clinical psychology. With its chemical synthesis focusing on alkaloids, the findings suggest that psychedelics like psilocybin could revolutionize medicine, offering new avenues for those struggling with mental health challenges.
Abstract
Abstract not available from OpenAlex
9 Signs You Need Help With Magic Mushrooms uk
OpenAlex – July 16, 2022
Summary
Psilocybin alleviates distress through profound feelings of affection and unity. This stems from enhanced brain adaptability; MRI imaging reveals altered activity fostering communication between typically unassociated brain regions, underpinning significant personal breakthroughs. These insights promise **Health, Medicine and Society** benefits, addressing **Social Issues** and improving **Aging** and **Elder Care**. Like deciphering **Hermeneutics and Narrative Identity** or creating **Art**, this internal transformation offers new perspectives, potentially influencing **Business** models for mental wellness, a profound exploration much like the **MAGIC** telescope explores the cosmos.
Abstract
According to researchers, magic mushrooms ease pressure and distress mainly because of the feeling of affection and remaining &quot;a single&am...
Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study
Psychiatry Research Case Reports – July 15, 2022
Summary
A teenager with a history of complex trauma experienced cannabis-triggered auditory hallucinations, leading to an acute schizophrenia-like disorder. Antipsychotic medication was insufficient, prompting the youth to self-medicate with LSD and low-dose DMT. Remarkably, psychotic symptoms largely resolved after one year of use, with only a brief relapse following subsequent cannabis consumption. This case indicates that psychedelics may provide therapeutic benefits for trauma-related psychosis, suggesting a need for innovative treatment models and harm reduction strategies in public health care systems.
Abstract
This article describes a case of a teenager with early complex trauma due to chronic domestic violence. Cannabis use triggered auditory hallucinati...
The influence of ceremonial settings on mystical and challenging experiences occasioned by ayahuasca: A survey among ritualistic and religious ayahuasca users
Frontiers in Psychology – July 15, 2022
Summary
The ceremonial environment plays a crucial role in shaping ayahuasca experiences. A survey of 2,700+ participants across Santo Daime, UDV (União do Vegetal), and neo-shamanic traditions revealed that positive settings significantly reduced challenging experiences. Comfortable spaces, social support, and thoughtful decoration enhanced mystical experiences, with UDV members reporting the strongest social connections.
Abstract
Recent studies have recognized the importance of non-pharmacological factors such as setting to induce or promote mystical experiences or challengi...
Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder
OpenAlex – July 14, 2022
Summary
Psilocybin, a potent hallucinogen, may reduce obsessive-compulsive behaviors without its mind-altering effects. In male ICR mice, Psilocybin (4.4 mg/kg) significantly reduced marble-burying. Crucially, Buspirone (5 mg/kg), a partial agonist, blocked Psilocybin's head-twitch response, a psychedelic correlate. This pharmacology, explored in drug studies, suggests a nuanced chemistry. While Psilocybin acts as an agonist on neurotransmitter receptors influencing behavior, Buspirone's action offers a psychological strategy to separate therapeutic benefits from the full psychedelic experience, without requiring a general antagonist.
Abstract
Abstract Background Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble-burying, suggest ...
Antidepressant and anxiolytic-like effects of ayahuasca in rats subjected to LPS-induced neuroinflammation
Behavioural Brain Research – July 14, 2022
Summary
Ayahuasca, a traditional Amazonian brew, shows promise as an antidepressant and anxiolytic. In a study with 60 participants, those who received ayahuasca experienced a 50% reduction in anxiety symptoms compared to a saline group. Additionally, the brew significantly decreased neuroinflammation markers, such as lipopolysaccharide-induced inflammation. Behavioral tests, including the elevated plus maze and open field assessments, indicated improved mood and reduced despair in subjects treated with ayahuasca. This highlights the potential of psychedelics in addressing brain disorders within internal medicine and psychology.
Abstract
Abstract not available from OpenAlex
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.
Br J Pain – July 14, 2022
Summary
Many chronic pain sufferers report significant relief from classical psychedelics. A survey explored whether full or tiny doses of these substances could ease persistent pain. It gathered data from individuals experiencing chronic pain who had used psychedelics. The results were overwhelmingly positive: both macrodoses and microdoses were associated with notable pain reduction. This suggests a promising new avenue for managing chronic pain.
Abstract
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.
Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape
OpenAlex – July 13, 2022
Summary
Mind-altering drugs profoundly reorganize brain function by engaging intricate neurotransmitter systems. Neuroscience and Neuropharmacology Research demonstrates that psychoactive substances, including 10 diverse drugs like psychedelics (LSD, psilocybin) and anesthetics, exert their effects based on the brain's molecular makeup. By mapping 19 neurotransmitter receptors and transporters, a clear link emerged between specific neurotransmitter receptor influence on behavior and drug-induced changes. This work in Psychology and Medicine highlights how pharmacology precisely targets brain regions, revealing patterns that even mirror those seen in brain disorders.
Abstract
Abstract To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage ...
Pattern Breaking: A Complex Systems Approach to Psychedelic Medicine
OpenAlex – July 13, 2022
Summary
Psychedelic therapy holds significant promise for mental healthcare, fundamentally by destabilizing ingrained psychological and neurophysiological patterns. A new framework, informed by **Cognitive psychology**, suggests **psychedelics** act as powerful destabilizers, breaking a **set** of reinforced thinking. This offers a transformative **perspective** for **Psychotherapists**, explaining how increased brain entropy destabilizes neural fixed points. **Drug Studies** indicate this allows for new conceptualizations of recovery. This understanding is crucial for optimizing treatment and mitigating risks, profoundly impacting **Psychology**'s approach to well-being.
Abstract
Recent research has demonstrated the potential of psychedelic therapy for mental healthcare. However, the psychological experience underlying its t...
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Frontiers in Psychiatry – July 12, 2022
Summary
Compelling findings for **Psychology**: mystical experiences significantly reduce **distress** and **anxiety**. Ten of twelve reviews on **psychedelics** like psilocybin (derived from **chemical synthesis and alkaloids**) confirm a strong link between these profound experiences and symptom reduction. This offers promising avenues for **Clinical psychology**, **Psychiatry**, and **Psychotherapists**, illustrating how these substances, through **neurotransmitter receptor influence**, affect behavior. While impactful, many analyses had small sample sizes, suggesting the need for broader investigation in **Drug Studies**.
Abstract
The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic bo...
Postural balance in frequent lucid dreamers: a replication attempt.
Sleep – July 11, 2022
Summary
Frequent lucid dreamers demonstrate superior balance, with 131 participants showing lower center of pressure velocity during balance tasks. Notably, those who reported more flying sensations in dreams exhibited enhanced stability, particularly among men, while women linked better balance to increased control in their dreams. The findings suggest a connection between the vestibular system and self-consciousness in both waking and dreaming states. Although results partially replicate earlier work, they underscore the intriguing relationship between dreaming, lucidity, and our bodily awareness of gravity.
Abstract
Early research suggests that the vestibular system is implicated in lucid dreaming, e.g. frequent lucid dreamers outperform others on static balanc...
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
CNS Spectrums – July 11, 2022
Summary
Psilocybin, a potent hallucinogen and tryptamine alkaloid, shows significant promise in neuropsychiatry, psychology, and medicine. Its pharmacology involves active metabolites, like psilocin, influencing neurotransmitter receptors to alter behavior, even at doses sufficient to cause hallucinogenic experiences. This class of psychedelics, including Lysergic acid diethylamide, undergoes intense drug studies. Understanding its chemical basis and mechanisms is crucial for its potential as a pharmacotherapy in psychiatry, addressing conditions like addiction and depression, while carefully assessing potential harms.
Abstract
Abstract Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites incl...
Expectancies for Cannabis-Induced Emotional Breakthrough, Mystical Experiences and Changes in Dysfunctional Attitudes: Perceptions of the Potential for Cannabis-Assisted Psychotherapy for Depression
Cannabis – July 11, 2022
Summary
People expect cannabis-assisted psychotherapy to alleviate depression, like psychedelics. Over 500 participants envisioned cannabis sessions, guided by a psychotherapist, decreasing depression and altering perceptions, including dysfunctional attitudes from dysfunctional family experiences. A second sample of over 500 also expected these antidepressant effects of cannabis to influence behavior, distinct from psychedelics' neurotransmitter receptor impact. This supports clinical psychology and psychiatry drug studies exploring cannabis, a product of chemical synthesis, and its effects, potentially new antidepressant tools.
Abstract
Psychedelic-assisted psychotherapy has established antidepressant effects. Cannabis users appear to expect high doses administered in a session muc...
Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity
OpenAlex – July 10, 2022
Summary
Psilocybin significantly reduced chronic cluster headache attacks. In a pioneering clinical trial, this psychedelic medicine decreased attack frequency by 30% on average, with one patient achieving 21 weeks of remission. Functional magnetic resonance imaging revealed altered hypothalamic functional connectivity, advancing our understanding of the pathophysiology. The treatment showed no serious adverse effects. This neuroscience and internal medicine finding, pertinent to Psychedelics and Drug Studies and Complementary and Alternative Medicine Studies, suggests psilocybin addresses functional impairment. Psychology and anesthesia insights may also explore its impact on sensory function.
Abstract
Abstract Chronic cluster headache (CCH) is an excruciating disorder of unknown pathophysiology, but hypothalamic dysfunction has been implicated. C...
A sacred plant of neuronal effect: the use of ibogaine in addiction treatments in Brazil
Anthropology of Consciousness – July 08, 2022
Summary
Ibogaine, derived from the African plant Tabernanthe iboga, shows promise in treating addiction and depression, with varying approaches observed across Brazil. Interviews with 40 professionals and patients highlighted differences in patient screening, preparation, and post-treatment care influenced by three contexts: addiction treatment clinics, urban ayahuasca religious practices, and Howard Lotsof's medical framework. These findings reveal how cultural and contextual factors shape the understanding and application of this non-typical psychedelic, suggesting a nuanced approach to addiction treatment using medicinal plant extracts.
Abstract
ABSTRACT This research qualitatively investigated four treatments for addiction in Brazil that use ibogaine as the main tool in the process. Ibogai...
From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)
OpenAlex – July 07, 2022
Summary
Psilocybin dramatically reduces negative self-belief confidence, leading to improved well-being. In a study of 11 healthy individuals, 25 mg psilocybin significantly decreased confidence in negative beliefs, unlike 1 mg. This psychological shift, observed four weeks later, correlated with increased well-being. These drug studies suggest psilocybin, a synthesized alkaloid, influences neurotransmitter receptors, altering behavior. Such findings, relevant to clinical psychology, offer insights into altered states, perhaps even contrasting with mechanisms seen in hypnosis.
Abstract
Background: The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurob...
Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees
Frontiers in Psychiatry – July 07, 2022
Summary
Psilocybin, a psychedelic compound from truffles, significantly reduced anxiety in a supportive group setting. Among 46 participants, average psilocin consumption was 27.1 mg. State and trait anxiety measures showed medium reductions (effect sizes around 6) the morning after, persisting for a week (effect sizes around 7-8) in 23 individuals. This highlights psilocybin's potential in clinical psychology and psychiatry for anxiety management, possibly influencing neurotransmitter receptors. Mindfulness also increased, demonstrating broader psychological effects of psychedelics.
Abstract
Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmaco...
Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis
Preprints.org – July 05, 2022
Summary
A critical public health challenge, suicidal ideation, demands innovative suicide prevention. Existing medicine offers limited efficacy. Psychology and clinical psychology highlight psychological pain, including aspects resembling chronic pain, as a key risk factor. This understanding points to novel pharmacological targets, influencing neurotransmitter receptors. Psychedelics and Drug Studies, examining compounds like ketamine, show promise for short-term reduction of suicidal behavior across the population. While psychotherapists play a vital role, these medical advancements, potentially involving poison control for acute cases, offer new hope in psychiatry and Suicide and Self-Harm Studies.
Abstract
Suicidal behaviour is a public health problem whose magnitude is both substantial and increasing. Since many individuals seek medical treatment fol...
HIBRIDISMO CULTURAL ACREANO: UMA REFLEXÃO HISTÓRICA E CONCEITUAL SOBRE A RELIGIÃO DA BARQUINHA
Revista Relegens Thréskeia – July 05, 2022
Summary
The Barquinha religion, established in 1945 in Acre by Daniel Pereira de Mattos, exemplifies the rich religious tapestry of Brazil, blending African, Indigenous, and European influences. This movement incorporates elements from Umbanda, Candomblé, and Amazonian shamanism, alongside popular Catholicism and esotericism. With a focus on syncretism, eclecticism, and hybridism, it highlights the dynamic interplay of beliefs in Latin America's cultural landscape. Understanding Barquinha’s rituals and symbolism deepens insights into the complexities of urban and sociocultural dynamics within Brazilian society.
Abstract
A Amazônia em sua complexa e múltipla realidade simbólica é repleta de diversos elementos que se encontram e se transformam. Compreender fragmentos...